Original investigationHeparin-induced thrombocytopenia in hemodialysis patients☆
References (19)
- et al.
Heparin-induced thrombocytopenia: Laboratory studies
Blood
(1988) - et al.
Effect of a new anticoagulant (MD805) on platelet activation in the hemodialysis circuit
Thromb Res
(1986) - et al.
A diagnostic test for heparin-induced thrombocytopenia
Blood
(1986) - et al.
Heparin-induced thrombocytopenia
Blut
(1989) Antigen generation in heparin-associated thrombocytopenia: The nonimmunologic type and the immunologic type are closely linked in their pathogenesis
Semin Thromb Hemost
(1995)- et al.
Heparin-induced thrombocytopenia with thrombosis and hemorrhage
Arch Surg
(1981) - et al.
Heparin-induced thrombocytopenia
Progr Hemost Thromb
(1991) - et al.
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia
Thromb Haemost
(1992) Heparin-induced thrombocytopenia and thrombosis
N Engl J Med
(1995)
There are more references available in the full text version of this article.
Cited by (145)
Mixed matrix membranes with incorporated glycosaminoglycans have good blood biocompatibility combined to high toxin removal
2024, Journal of Membrane ScienceImmunologic Effects of Heparin Associated With Hemodialysis: Focus on Heparin-Induced Thrombocytopenia
2024, Seminars in NephrologyAmerican Society of Hematology 2018 guidelines for management of venous thromboembolism: Heparin-induced thrombocytopenia
2018, Blood AdvancesCitation Excerpt :We identified nonrandomized studies evaluating the use of argatroban, danaparoid, fondaparinux, bivalirudin, and rivaroxaban. Ten studies reported on treatment with argatroban,111-120 3 studies reported on treatment with danaparoid,70,121,122 3 studies reported on treatment with fondaparinux,123-125 2 studies reported on treatment with bivalirudin,57,126 and 1 study reported on treatment with rivaroxaban.127 These studies reported on the outcomes of bleeding, thromboembolic events, mortality, and serious adverse events.
- ☆
Supported in part by a grant from the Heparin Conference (1995).
Copyright © 1996 Published by Elsevier Inc.